Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02612207 · ClinicalTrials.gov registry record
Point-of-Care System for Determination of Bilirubin Capacity in Neonates
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 161
- Enrollment target
NCT02612207: Completed study, sponsored by Stanford University.
NCT02612207 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 161 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02612207 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 161 participants
- Enrollment target
Study Summary
The aims of this observational bench project are to validate the performance of the miniaturized and modernized hematofluorometer that measures bilirubin capacity into a product and is suitable for operation in various point of care environments w in the management of preterm neonates.
Primary Outcome
To define normative data (mean, median, range, inter-quartile ranges) among these deemed healthy infants (including those who are at- risk) for increased vulnerability to impaired binding soon after birth
Interventions
- DEVICE Bilirubin Binding Capacity by Hematofluorometry Validation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2015-08-01 |
| Est. Completion | 2018-08-31 |
What the finished NCT02612207 record still lists
NCT02612207 is an observational study that tracks outcomes without assigning an intervention. The registered 161 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Bilirubin Binding Capacity by Hematofluorometry Validation is the first listed.
NCT02612207 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02612207 about?
NCT02612207 is a clinical study titled "Point-of-Care System for Determination of Bilirubin Capacity in Neonates". The aims of this observational bench project are to validate the performance of the miniaturized and modernized hematofluorometer that measures bilirubin capacity into a product and is suitable for operation in various point of care environments w in the management of preterm neonates.
What is the current status of trial NCT02612207?
This trial is currently completed. The enrollment target is 161 participants. The study started on 2015-08-01. Estimated completion is 2018-08-31.
What interventions are being tested in trial NCT02612207?
The interventions under investigation include: Bilirubin Binding Capacity by Hematofluorometry Validation (DEVICE).
Who is sponsoring clinical trial NCT02612207?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06391034 · 161 participants · Phase 2
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
- NCT06546670 · 161 participants · Phase 1
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- NCT06616766 · 161 participants · Phase 1
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
- NCT06752356 · 161 participants · Phase 3
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI